These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23849895)

  • 1. ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma.
    Johnson H; Zhou M; Osunkoya AO
    Hum Pathol; 2013 Oct; 44(10):2241-6. PubMed ID: 23849895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN Expression in Mucinous Prostatic Adenocarcinoma, Prostatic Adenocarcinoma With Mucinous Features, and Adjacent Conventional Prostatic Adenocarcinoma: A Multi-institutional Study of 92 Cases.
    Bertsch EC; Magi-Galluzzi C; Cheng L; Osunkoya AO
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):225-230. PubMed ID: 29621096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.
    Green WM; Hicks JL; De Marzo A; Illei PP; Epstein JI
    Hum Pathol; 2013 Sep; 44(9):1895-901. PubMed ID: 23664537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
    He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
    Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
    Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
    Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy.
    Osunkoya AO; Adsay NV; Cohen C; Epstein JI; Smith SL
    Mod Pathol; 2008 Jul; 21(7):789-94. PubMed ID: 18487999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
    Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
    J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.
    Kimura T; Furusato B; Miki J; Yamamoto T; Hayashi N; Takahashi H; Kamata Y; van Leenders GJ; Visakorpi T; Egawa S
    Pathol Int; 2012 Nov; 62(11):742-8. PubMed ID: 23121605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
    Xu B; Chevarie-Davis M; Chevalier S; Scarlata E; Zeizafoun N; Dragomir A; Tanguay S; Kassouf W; Aprikian A; Brimo F
    Hum Pathol; 2014 Mar; 45(3):488-97. PubMed ID: 24406017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.
    Yaskiv O; Zhang X; Simmerman K; Daly T; He H; Falzarano S; Chen L; Magi-Galluzzi C; Zhou M
    Am J Surg Pathol; 2011 Jul; 35(7):1062-8. PubMed ID: 21623182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients.
    Furusato B; van Leenders GJ; Trapman J; Kimura T; Egawa S; Takahashi H; Furusato M; Visakorpi T; Hano H
    Pathol Int; 2011 Jul; 61(7):409-14. PubMed ID: 21707844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERG expression in prostate cancer: the prognostic paradox.
    Taris M; Irani J; Blanchet P; Multigner L; Cathelineau X; Fromont G
    Prostate; 2014 Nov; 74(15):1481-7. PubMed ID: 25175352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma.
    Schneider TM; Osunkoya AO
    Mod Pathol; 2014 Aug; 27(8):1174-8. PubMed ID: 24406865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
    Lippolis G; Edsjö A; Stenman UH; Bjartell A
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucin-producing tumors and tumor-like lesions involving the prostate: a comprehensive review.
    Bohman KD; Osunkoya AO
    Adv Anat Pathol; 2012 Nov; 19(6):374-87. PubMed ID: 23060063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.
    He H; Osunkoya AO; Carver P; Falzarano S; Klein E; Magi-Galluzzi C; Zhou M
    BJU Int; 2012 Dec; 110(11 Pt B):E751-5. PubMed ID: 23046279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.